Leydig cell function in male survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study
Journal of Clinical Oncology Nov 18, 2019
Chemaitilly W, Liu Q, van Iersel L, et al. - Given that direct evaluation of Leydig cell function in childhood cancer survivors has been limited, researchers undertook this retrospective analysis with cross-sectional health outcomes analysis, to determine how prevalent are Leydig cell failure (LCF), Leydig cell dysfunction (LCD), and related adverse health outcomes, and to define the factors that confer risk for these in male childhood cancer survivors. Following cancer diagnosis, 1,516 participants with a median age of 30.8 years were assessed at a median of 22.0 years. Serum total testosterone less than 250 ng/dL (or 8.67 nmol/L) and luteinizing hormone greater than 9.85 IU/L defined LCF, and testosterone as 250 ng/dL or greater and luteinizing hormone greater than 9.85 IU/L defined LCD. The prevalence of LCF was estimated to be 6.9% and that of LCD was 14.7%. Findings revealed the link of older age, testicular radiotherapy, and exposure to alkylating agents, with LCF, which was found to be related to adverse physical and psychosexual consequences. Similar risk factors were reported for LCD. There was no link of LCD with adverse health outcomes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries